IN2012DN03045A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03045A
IN2012DN03045A IN3045DEN2012A IN2012DN03045A IN 2012DN03045 A IN2012DN03045 A IN 2012DN03045A IN 3045DEN2012 A IN3045DEN2012 A IN 3045DEN2012A IN 2012DN03045 A IN2012DN03045 A IN 2012DN03045A
Authority
IN
India
Prior art keywords
receptor
compounds
medicaments
antagonists
concerned
Prior art date
Application number
Inventor
Johannes Aebi
Alfred Binggeli
Luke Green
Guido Hartmann
Hans P Maerki
Patrizio Mattei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03045A publication Critical patent/IN2012DN03045A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9,and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
IN3045DEN2012 2009-10-21 2010-10-18 IN2012DN03045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09173682 2009-10-21
PCT/EP2010/065579 WO2011048032A1 (en) 2009-10-21 2010-10-18 Diazepam derivatives as modulators of chemokine receptors

Publications (1)

Publication Number Publication Date
IN2012DN03045A true IN2012DN03045A (en) 2015-07-31

Family

ID=43087104

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3045DEN2012 IN2012DN03045A (en) 2009-10-21 2010-10-18

Country Status (13)

Country Link
US (1) US8445674B2 (en)
EP (1) EP2491022B1 (en)
JP (1) JP5654027B2 (en)
KR (1) KR20120070609A (en)
CN (1) CN102762541B (en)
AU (1) AU2010309920A1 (en)
BR (1) BR112012009661A2 (en)
CA (1) CA2776914A1 (en)
ES (1) ES2531986T3 (en)
IL (1) IL218795A0 (en)
IN (1) IN2012DN03045A (en)
MX (1) MX2012004112A (en)
WO (1) WO2011048032A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2764840T3 (en) 2015-01-28 2020-06-04 Univ Bordeaux Use of plerixafor to treat and / or prevent acute exacerbations of chronic obstructive pulmonary disease
JP2018527337A (en) 2015-08-13 2018-09-20 ファイザー・インク Bicyclic fused heteroaryl or aryl compounds
CN105906553B (en) * 2016-04-21 2019-01-29 重庆威尔德·浩瑞医药化工有限公司 A kind of synthetic method of N- benzyl -4- methyl piperidine -3- keto hydrochloride
CN107216335B (en) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 A kind of tert-butyl 1- (methylol) -3- oxa- -9- azaspiro [5.5] hendecane -9- formic acid base ester preparation method
KR101938991B1 (en) 2017-09-25 2019-01-15 강원대학교산학협력단 Pharmaceutical composition for treating and preventing diabetic complications
CN111423454B (en) * 2020-04-24 2021-06-22 苏州大学 Piperazine compounds and their application in the preparation of chemokine receptor CCR2 antagonists
CN113200997B (en) * 2021-05-07 2023-10-03 上海合全医药有限公司 Synthesis method of 2, 5-dioxa-8-azaspiro [3.5] nonane and salt thereof
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
SG131946A1 (en) * 2003-10-24 2007-05-28 Hoffmann La Roche Ccr3 receptor antagonists
WO2005079769A2 (en) * 2004-02-24 2005-09-01 Schering Aktiengesellschaft Piperazine derivatives for the treatment of endometriosis
JP2007269629A (en) * 2004-06-21 2007-10-18 Astellas Pharma Inc Quinazoline derivatives
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
JP2010208945A (en) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp Heterocyclic compound
KR20100033544A (en) 2007-07-19 2010-03-30 에프. 호프만-라 로슈 아게 Novel heterocyclyl compounds and their use as chemokine antagonists
CA2730770A1 (en) * 2008-07-28 2010-02-04 F. Hoffmann-La Roche Ag Diazepan and piperazine derivatives modulators of chemokine receptors
WO2011002067A1 (en) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Heterocyclic compound and use thereof

Also Published As

Publication number Publication date
US20110092698A1 (en) 2011-04-21
EP2491022B1 (en) 2014-12-31
CN102762541B (en) 2016-03-16
CA2776914A1 (en) 2011-04-28
IL218795A0 (en) 2012-06-28
CN102762541A (en) 2012-10-31
AU2010309920A1 (en) 2012-06-07
JP2013508328A (en) 2013-03-07
US8445674B2 (en) 2013-05-21
JP5654027B2 (en) 2015-01-14
ES2531986T3 (en) 2015-03-23
BR112012009661A2 (en) 2016-05-17
MX2012004112A (en) 2012-05-08
KR20120070609A (en) 2012-06-29
EP2491022A1 (en) 2012-08-29
WO2011048032A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2009010429A3 (en) Novel heterocyclyl compounds and their use as chemokine antagonists
IN2012DN03045A (en)
MX2009009690A (en) Thiazolidine derivatives as orexin receptor antagonists.
MX2010008993A (en) 2-aza-bicyclo[2.2.1]heptane derivatives.
MX2010003621A (en) New biaryl derivatives.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
MX2009014002A (en) Imidazole derivatives as ccr2 receptor antagonists.
ATE483707T1 (en) 2-CYCLOPROPYLTHIAZOLE DERIVATIVES
ATE524466T1 (en) 3-AZABICYCLOÄ3.3.0ÜOCTANE COMPOUNDS
TW200738655A (en) Novel bicyclic sulfonamide derivatives
MY161903A (en) Substituted piperidines as ccr3 antagonists
MX2011012017A (en) Azacyclic spiroderivatives as hsl inhibitors.
NO20084332L (en) Diazepan derivatives modulators for chemokine receptors
IN2012DN03337A (en)
WO2009013211A3 (en) New pyrazol derivatives
TN2011000438A1 (en) Compounds as bradykinin b1 antagonists
TW200745032A (en) Novel heterobicyclic derivatives
PH12013500942A1 (en) Triazolopyridine compounds
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX2010002760A (en) Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists.
MX2009003645A (en) N-substituted-azacyclylamines as histamine-3 antagonists.
IN2012DN01232A (en)
MX2011008360A (en) Heteroaryl substituted pyridazinone derivatives.
CL2011000533A1 (en) Substituted isoquinoline derived compounds; nk3 antagonist; pharmaceutical composition comprising it; and use in the treatment of diseases such as psychosis, schizophrenia, Alzheimer's, Parkinson's, among others.
MX2009008323A (en) Heterocyclic derivatives as m3 muscarinic receptors.